Alamar Biosciences, Inc.
12 articles about Alamar Biosciences, Inc.
-
Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research
4/4/2024
Biognosys and Alamar Biosciences, Inc. are pleased to announce a strategic partnership aimed at advancing scientific discovery in the field of biofluid proteomics biomarkers.
-
Alamar Biosciences Announces the Commercial Launch of Ultra-high Sensitivity NULISAseq™ CNS Disease Panel 120 and NULISAqpcr™ pTau-217 Assays
3/5/2024
Alamar Biosciences announced today the commercial launch of the NULISAseq CNS Disease Panel 120 for highly multiplexed protein analysis of all the critical pathways implicated in major neurological disorders, and the NULISAqpcr pTau-217 Assay
-
Alamar Biosciences and ALZpath, Inc. Announce Strategic Supply Agreement for pTau217 Antibody to Advance Alzheimer's Disease Research
2/29/2024
Alamar Biosciences is pleased to announce a strategic supply agreement with ALZpath, a leading developer of diagnostic solutions in Alzheimer's disease and related dementias.
-
Alamar Biosciences Raises $128 Million in Oversubscribed Series C Financing to Accelerate Commercialization of its Proteomics Platform
2/26/2024
Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, announced the first close of $100 million in Series C financing with the second close of an additional $28 million expected to happen within the next 30 days.
-
Alamar Biosciences Announces Commercial Launch of the ARGO™ HT System and the NULISAseq™ Inflammation Panel 250 for Ultra-high Sensitivity Protein Analysis in Biofluids
1/4/2024
Alamar Biosciences announced the commercial launch of the ARGO HT System for push-button, high sensitivity analysis of proteins in biofluids and the NULISAseq Inflammation Panel 250 for deep profiling of immune response.
-
Alamar Biosciences Announces Seminal Publication in Nature Communications Demonstrating Superior Performance of the NULISA™ Platform
11/9/2023
Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, announced the first publication of a paper in Nature Communications on the development and validation of its NULISA technology.
-
Alamar Biosciences Unveils Novel Proteomics Platform with Best-in-Class Sensitivity and High Multiplexing Capability
4/12/2023
Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, announced the unveiling of its technology platform NULISA™, a novel automated ultrasensitive and highly multiplexed proteomics technology for liquid biopsy.
-
Mologic and Alamar Biosciences collaborate to develop a next generation COVID-19 antigen test
5/4/2022
Alamar Biosciences (Alamar), and Mologic, Ltd. (Mologic), today announced a collaboration to utilize Alamar's novel antibodies against SARS-CoV-2 Nucleocapsid (N) protein for Mologic's future COVID-19 RDTs.
-
SciNeuro Pharmaceuticals and Alamar Biosciences Collaborate to Discover Novel Therapeutic Antibodies for CNS Diseases
2/15/2022
Alamar Biosciences and SciNeuro Pharmaceuticals announced a multi-program collaboration and license agreement to discover and develop novel therapeutic antibodies for targets selected by SciNeuro within the field of neurological diseases, based on Alamar's Attobody platform.
-
Antibody research on cancer and neurological diseases is prioritized in series of biopharma research agreements.
-
Alamar Biosciences partners with Abcam to drive understanding of the human proteome
1/4/2022
Alamar selects Abcam as a key provider of antibody content for its propriety NULISA technology platform.
-
Alamar Biosciences Completes $80M Series B Fundraising to Bring Unprecedented Performance to the Proteomics Market
9/8/2021
Alamar Biosciences, Inc. announced today that it has closed its $80 million Series B financing round, bringing its total funding to $110 million .